Literature DB >> 9696855

Complete bovine leukemia virus (BLV) provirus is conserved in BLV-infected cattle throughout the course of B-cell lymphosarcoma development.

S Tajima1, Y Ikawa, Y Aida.   

Abstract

Bovine leukemia virus (BLV) and human T-cell leukemia virus types 1 and 2 (HTLV-1 and HTLV-2) belong to the same subfamily of oncoviruses. Defective HTLV-1 proviral genomes have been found in more than half of all patients with adult T-cell leukemia examined. We have characterized the genomic structure of integrated BLV proviruses in peripheral blood lymphocytes and tumor tissue taken from animals with lymphomas at various stages. Genomic Southern hybridization with SacI, which generates two major fragments of BLV proviral DNA, yielded only bands that corresponded to a full-size provirus in all of 23 cattle at the lymphoma stage and in 7 BLV-infected but healthy cattle. Long PCR with primers located in long terminal repeats clearly demonstrated that almost the complete provirus was retained in all of 27 cattle with lymphomas and in 19 infected but healthy cattle. However, in addition to a PCR product that corresponded to a full-size provirus, a fragment shorter than that of the complete virus was produced in only one of the 27 animals with lymphomas. Moreover, when we performed conventional PCR with a variety of primers that spanned the entire BLV genome to detect even small defects, PCR products were produced that specifically covered the entire BLV genome in all of the 40 BLV-infected cattle tested. Therefore, it appears that at least one copy of the full-length BLV proviral genome was maintained in each animal throughout the course of the disease and, in addition, that either large or small deletions of proviral genomes may be very rare events in BLV-infected cattle.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9696855      PMCID: PMC110004     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Sequence variability of bovine leukemia virus env gene and its relevance to the structure and antigenicity of the glycoproteins.

Authors:  R Z Mamoun; M Morisson; N Rebeyrotte; B Busetta; D Couez; R Kettmann; M Hospital; B Guillemain
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

2.  Further phenotypic characterization of target cells for bovine leukemia virus experimental infection in sheep.

Authors:  Y Aida; M Miyasaka; K Okada; M Onuma; S Kogure; M Suzuki; P Minoprio; D Levy; Y Ikawa
Journal:  Am J Vet Res       Date:  1989-11       Impact factor: 1.156

3.  Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia.

Authors:  S Tamiya; M Matsuoka; K Etoh; T Watanabe; S Kamihira; K Yamaguchi; K Takatsuki
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

4.  In vitro and in vivo oncogenic potential of bovine leukemia virus G4 protein.

Authors:  P Kerkhofs; H Heremans; A Burny; R Kettmann; L Willems
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

5.  Transcriptional activation of bovine leukemia virus in blood cells from experimentally infected, asymptomatic sheep with latent infections.

Authors:  D M Lagarias; K Radke
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

6.  Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease.

Authors:  K Tsukasaki; H Tsushima; M Yamamura; T Hata; K Murata; T Maeda; S Atogami; H Sohda; S Momita; S Ideda; S Katamine; Y Yamada; S Kamihira; M Tomonaga
Journal:  Blood       Date:  1997-02-01       Impact factor: 22.113

7.  Cellular pathways involved in the ex vivo expression of bovine leukemia virus.

Authors:  P Kerkhofs; E Adam; L Droogmans; D Portetelle; M Mammerickx; A Burny; R Kettmann; L Willems
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  Transmission and propagation in cell culture of virus produced by cells transfected with an infectious molecular clone of bovine leukemia virus.

Authors:  K Inabe; K Ikuta; Y Aida
Journal:  Virology       Date:  1998-05-25       Impact factor: 3.616

9.  In vivo transcription of the bovine leukemia virus tax/rex region in normal and neoplastic lymphocytes of cattle and sheep.

Authors:  W A Jensen; J Rovnak; G L Cockerell
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

10.  Bovine leukemia virus trans-activator p38tax activates heterologous promoters with a common sequence known as a cAMP-responsive element or the binding site of a cellular transcription factor ATF.

Authors:  I Katoh; Y Yoshinaka; Y Ikawa
Journal:  EMBO J       Date:  1989-02       Impact factor: 11.598

View more
  18 in total

1.  The region between amino acids 245 and 265 of the bovine leukemia virus (BLV) tax protein restricts transactivation not only via the BLV enhancer but also via other retrovirus enhancers.

Authors:  S Tajima; Y Aida
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Suppression of viral gene expression in bovine leukemia virus-associated B-cell malignancy: interplay of epigenetic modifications leading to chromatin with a repressive histone code.

Authors:  Makram Merimi; Pavel Klener; Maud Szynal; Yvette Cleuter; Pierre Kerkhofs; Arsène Burny; Philippe Martiat; Anne Van den Broeke
Journal:  J Virol       Date:  2007-03-28       Impact factor: 5.103

3.  Latency of viral expression in vivo is not related to CpG methylation in the U3 region and part of the R region of the long terminal repeat of bovine leukemia virus.

Authors:  Shigeru Tajima; Masako Tsukamoto; Yoko Aida
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

4.  A mutant form of the tax protein of bovine leukemia virus (BLV), with enhanced transactivation activity, increases expression and propagation of BLV in vitro but not in vivo.

Authors:  Shigeru Tajima; Masahiko Takahashi; Shin-Nosuke Takeshima; Satoru Konnai; Shan Ai Yin; Shinobu Watarai; Yoshimasa Tanaka; Misao Onuma; Kosuke Okada; Yoko Aida
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

5.  BLV-CoCoMo-qPCR: a useful tool for evaluating bovine leukemia virus infection status.

Authors:  Mayuko Jimba; Shin-Nosuke Takeshima; Hironobu Murakami; Junko Kohara; Naohiko Kobayashi; Tamako Matsuhashi; Takashi Ohmori; Tetsuo Nunoya; Yoko Aida
Journal:  BMC Vet Res       Date:  2012-09-21       Impact factor: 2.741

6.  BLV-CoCoMo-qPCR: Quantitation of bovine leukemia virus proviral load using the CoCoMo algorithm.

Authors:  Mayuko Jimba; Shin-nosuke Takeshima; Kazuhiro Matoba; Daiji Endoh; Yoko Aida
Journal:  Retrovirology       Date:  2010-11-02       Impact factor: 4.602

7.  Estimation of bovine leukemia virus (BLV) proviral load harbored by lymphocyte subpopulations in BLV-infected cattle at the subclinical stage of enzootic bovine leucosis using BLV-CoCoMo-qPCR.

Authors:  Carlos Javier Panei; Shin-nosuke Takeshima; Takashi Omori; Tetsuo Nunoya; William C Davis; Hiroshi Ishizaki; Kazuhiro Matoba; Yoko Aida
Journal:  BMC Vet Res       Date:  2013-05-04       Impact factor: 2.741

8.  Animal models on HTLV-1 and related viruses: what did we learn?

Authors:  Hiba El Hajj; Rihab Nasr; Youmna Kfoury; Zeina Dassouki; Roudaina Nasser; Ghada Kchour; Olivier Hermine; Hugues de Thé; Ali Bazarbachi
Journal:  Front Microbiol       Date:  2012-09-21       Impact factor: 5.640

Review 9.  Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human.

Authors:  Nicolas Gillet; Arnaud Florins; Mathieu Boxus; Catherine Burteau; Annamaria Nigro; Fabian Vandermeers; Hervé Balon; Amel-Baya Bouzar; Julien Defoiche; Arsène Burny; Michal Reichert; Richard Kettmann; Luc Willems
Journal:  Retrovirology       Date:  2007-03-16       Impact factor: 4.602

Review 10.  Mechanisms of pathogenesis induced by bovine leukemia virus as a model for human T-cell leukemia virus.

Authors:  Yoko Aida; Hironobu Murakami; Masahiko Takahashi; Shin-Nosuke Takeshima
Journal:  Front Microbiol       Date:  2013-11-08       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.